Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.36 |
| ▸ | GRM5 | P41594 | 5/20 | 0.36 |
| ▸ | CLK2 | P49760 | 2/20 | 0.35 |
| ▸ | CLK3 | P49761 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | WNT1 | P04628 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.34 |
| ▸ | FYN | P06241 | 2/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13312192 | 0.72 | SLC5A1 (0.40) | — | |
| SCHEMBL3502016 | 0.71 | HDAC2 (0.45) | HDAC2HDAC1 | |
| SCHEMBL31106073 | 0.69 | NPC1 (0.41) | HDAC1 | |
| SCHEMBL31105898 | 0.68 | LCK (0.38) | FYN | |
| SCHEMBL31105886 | 0.67 | LCK (0.38) | DYRK1AFYN | |
| SCHEMBL31106135 | 0.67 | LCK (0.36) | FYN | |
| SCHEMBL14764815 | 0.64 | MAP2K4 (0.51) | HDAC2HDAC1GSK3B | |
| SCHEMBL23540051 | 0.64 | HDAC3 (0.39) | HDAC2HDAC3HDAC1HDAC4HDAC7 | |
| SCHEMBL2358021 | 0.64 | SLC5A1 (0.42) | HDAC2HDAC3HDAC1GSK3BDYRK1A | |
| SCHEMBL21275920 | 0.63 | HDAC2 (0.55) | HDAC2HDAC3HDAC1HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2108644-B1 | N-(Methyl)-pyridin-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins | AC IMMUNE SA (CH) | 2016-07-20 | — | — | EP | disclosed |
| US-8673940-B2 | Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | AC IMMUNE SA (CH) | 2014-03-18 | — | — | US | disclosed |
| US-8673940-B2 | Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | AC IMMUNE SA (CH) | 2014-03-18 | — | — | US | disclosed |
| US-8673940-B2 | Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | AC IMMUNE SA (CH) | 2014-03-18 | — | — | US | disclosed |
| US-20120309791-A1 | NOVEL COMPOUND FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2012-12-06 | — | — | US | disclosed |
| US-20120309791-A1 | NOVEL COMPOUND FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2012-12-06 | — | — | US | disclosed |
| US-20120309791-A1 | NOVEL COMPOUND FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2012-12-06 | — | — | US | disclosed |
| US-20100183513-A1 | N-(METHYL) -1H-PYRAZOL-3-AMINE, N-(METHYL)-PYRIDIN-2-AMINE AND N-(METHYL)-THIAZOL-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S | AC IMMUNE SA (CH) | 2010-07-22 | — | — | US | disclosed |
| US-20100183513-A1 | N-(METHYL) -1H-PYRAZOL-3-AMINE, N-(METHYL)-PYRIDIN-2-AMINE AND N-(METHYL)-THIAZOL-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S | AC IMMUNE SA (CH) | 2010-07-22 | — | — | US | disclosed |
| US-20100183513-A1 | N-(METHYL) -1H-PYRAZOL-3-AMINE, N-(METHYL)-PYRIDIN-2-AMINE AND N-(METHYL)-THIAZOL-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S | AC IMMUNE SA (CH) | 2010-07-22 | — | — | US | disclosed |
| EP-2108644-A1 | N-(methyl)-pyridin-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins | AC Immune S.A. (CH) | 2009-10-14 | — | — | EP | disclosed |
| EP-2102165-A2 | N-(METHYL)-1H-PYRAZOL-3-AMINE, N-(METHYL)-PYRIDIN-2-AMINE AND N-(METHYL)-THIAZOL-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S | AC Immune S.A. (CH) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008061795-A2 | N- (METHYL) -1H- PYRAZOL- 3 -AMINE, N- (METHYL) -PYRIDIN-2-AMINE AND N- (METHYL) -THIAZ0L-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S | AC IMMUNE SA (CH) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183513-A1 | N-(METHYL) -1H-PYRAZOL-3-AMINE, N-(METHYL)-PYRIDIN-2-AMINE AND N-(METHYL)-THIAZOL-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S | PSEN2, APP, PSEN1 | PTPN11 3685/4885HDAC2 2243/4885HDAC3 4083/4885 |
| US-20120309791-A1 | NOVEL COMPOUND FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | APP, PSEN2, PSEN1 | PTPN11 4661/4885HDAC2 3881/4885HDAC3 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.